ES2745532T3 - Sobetirome en el tratamiento de enfermedades de mielinización - Google Patents

Sobetirome en el tratamiento de enfermedades de mielinización Download PDF

Info

Publication number
ES2745532T3
ES2745532T3 ES14791718T ES14791718T ES2745532T3 ES 2745532 T3 ES2745532 T3 ES 2745532T3 ES 14791718 T ES14791718 T ES 14791718T ES 14791718 T ES14791718 T ES 14791718T ES 2745532 T3 ES2745532 T3 ES 2745532T3
Authority
ES
Spain
Prior art keywords
sobetirome
disease
pharmaceutically acceptable
acceptable salt
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14791718T
Other languages
English (en)
Spanish (es)
Inventor
Meredith Hartley
Andrew Placzek
Marco Righi
Dennis Bourdette
Gail Marracci
Priya Chaudhary
Thomas S Scanlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
US Department of Veterans Affairs
Original Assignee
Oregon Health and Science University
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University, US Department of Veterans Affairs filed Critical Oregon Health and Science University
Application granted granted Critical
Publication of ES2745532T3 publication Critical patent/ES2745532T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ES14791718T 2013-05-03 2014-02-05 Sobetirome en el tratamiento de enfermedades de mielinización Active ES2745532T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819467P 2013-05-03 2013-05-03
PCT/US2013/053640 WO2014178892A1 (en) 2013-05-03 2013-08-05 Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
PCT/US2014/014943 WO2014178931A1 (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases

Publications (1)

Publication Number Publication Date
ES2745532T3 true ES2745532T3 (es) 2020-03-02

Family

ID=51843844

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14791718T Active ES2745532T3 (es) 2013-05-03 2014-02-05 Sobetirome en el tratamiento de enfermedades de mielinización

Country Status (12)

Country Link
US (3) US10226438B2 (enExample)
EP (1) EP2991670B8 (enExample)
JP (4) JP2016517883A (enExample)
CN (1) CN105431163A (enExample)
AU (1) AU2014260468A1 (enExample)
BR (1) BR112015027682A2 (enExample)
CA (1) CA2911309A1 (enExample)
ES (1) ES2745532T3 (enExample)
MX (2) MX379043B (enExample)
RU (1) RU2015151216A (enExample)
SG (2) SG11201509012QA (enExample)
WO (2) WO2014178892A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517883A (ja) * 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
JP6302091B2 (ja) 2014-04-30 2018-03-28 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマー組成物および眼の疾患の処置におけるその使用
JP6342575B2 (ja) 2014-08-13 2018-06-13 ザ・ジョンズ・ホプキンス・ユニバーシティー 脳腫瘍への選択的デンドリマー送達
WO2017075580A1 (en) * 2015-10-29 2017-05-04 The Johns Hopkins University Compositions and methods for treatment of peroxisomal disorders and leukodystrophies
KR102407053B1 (ko) * 2016-04-22 2022-06-10 바이킹 테라퓨틱스 인코포레이티드 갑상선 베타-작용제의 사용
ES2992773T3 (en) 2016-04-22 2024-12-18 Viking Therapeutics Inc Use of thyroid beta-agonists
KR102331596B1 (ko) * 2016-05-18 2021-11-25 오레곤 헬스 앤드 사이언스 유니버시티 소베티롬의 유도체
US11325886B2 (en) 2016-08-12 2022-05-10 Oregon Health & Science University Amide compounds, pharmaceutical compositions thereof, and methods of using the same
WO2018183940A1 (en) * 2017-03-31 2018-10-04 Neurovia, Inc. Methods and compositions for treating niemann-pick disease
EP3615086A4 (en) 2017-04-27 2021-01-06 The Johns Hopkins University COMPOSITIONS OF DENDRIMERS FOR USE IN ANGIOGRAPHY
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US10780069B2 (en) * 2017-05-18 2020-09-22 University of Pittsburgh—of the Commonwealth System of Higher Education Use of GC-1 in transplant related population
US11660281B2 (en) 2017-06-29 2023-05-30 Yale University Compositions and methods of treating or preventing fibrotic lung diseases
JP7109794B2 (ja) 2017-07-18 2022-08-02 慶應義塾 Ｔｈ１細胞誘導性細菌に対する抗菌組成物
CN111615528A (zh) 2017-11-10 2020-09-01 约翰霍普金斯大学 树枝状聚合物递送系统和其使用方法
CA3122996A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
EP3931180A1 (en) 2019-03-01 2022-01-05 Autobahn Therapeutics, Inc. Novel thyromimetics
KR20220121239A (ko) 2019-11-29 2022-08-31 아우토반 쎄라퓨틱스, 인크. 신규한 갑상선 호르몬 모방제
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物
CN115569233B (zh) * 2022-10-17 2023-07-14 湖南大学 既能吸光又能与自由基反应的高效光抑制剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
EP0873361B1 (en) 1995-12-13 2006-11-02 The Regents Of The University Of California Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand
US6054485A (en) 1996-08-20 2000-04-25 Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
EP1598334A1 (en) 1998-06-30 2005-11-23 The Regents Of The University Of California Thyroid hormone analogues and methods for their preparation
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
EP2335694B1 (en) * 2003-09-15 2018-06-13 NanoPharmaceuticals LLC Thyroid hormone analogs and methods of use
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
WO2006012015A2 (en) 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
CN101102758B (zh) 2004-09-15 2011-11-16 奥德威研究院 促进血管新生的甲状腺激素类似物
US20090117054A1 (en) 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
WO2008049053A2 (en) * 2006-10-20 2008-04-24 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
CA2704279C (en) * 2006-11-03 2014-09-30 University Of Saskatchewan Method of treating demyelination diseases
FI20075245A0 (fi) * 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
CA2970273C (en) * 2007-07-11 2020-04-14 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
MX2011012078A (es) 2009-05-20 2012-03-14 Lingual Consegna Pty Ltd Formulacion terapeutica bucal y/o sublingual.
TW201221505A (en) * 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EA031156B1 (ru) 2010-12-16 2018-11-30 Суновион Фармасьютикалз Инк. Сублингвальные пленки
EP2911924B1 (en) * 2012-10-25 2017-06-21 Volvo Truck Corporation Electronically controlled pneumatic brake system for an automotive vehicle, automotive vehicle equipped with such a system and method for controlling such a system
JP2016517883A (ja) 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用

Also Published As

Publication number Publication date
EP2991670B8 (en) 2019-09-11
MX2015015228A (es) 2016-10-03
JP2018141024A (ja) 2018-09-13
US20160081955A1 (en) 2016-03-24
US20200405669A1 (en) 2020-12-31
WO2014178931A8 (en) 2015-11-26
EP2991670B1 (en) 2019-07-03
RU2015151216A (ru) 2017-06-08
BR112015027682A2 (pt) 2017-08-29
CA2911309A1 (en) 2014-11-06
MX2021000538A (es) 2021-04-28
JP2016517883A (ja) 2016-06-20
US20190175531A1 (en) 2019-06-13
MX379043B (es) 2025-03-10
US10226438B2 (en) 2019-03-12
JP6360552B2 (ja) 2018-07-18
WO2014178892A8 (en) 2015-12-17
WO2014178892A1 (en) 2014-11-06
SG11201509012QA (en) 2015-11-27
EP2991670A4 (en) 2017-01-18
JP6360552B6 (ja) 2018-08-15
JP2016517884A (ja) 2016-06-20
SG10201709090UA (en) 2017-12-28
AU2014260468A1 (en) 2015-11-19
US11510887B2 (en) 2022-11-29
WO2014178931A1 (en) 2014-11-06
EP2991670A1 (en) 2016-03-09
HK1222552A1 (en) 2017-07-07
JP2018162321A (ja) 2018-10-18
CN105431163A (zh) 2016-03-23

Similar Documents

Publication Publication Date Title
ES2745532T3 (es) Sobetirome en el tratamiento de enfermedades de mielinización
US20240024271A1 (en) Methods and Compositions for Preventing and Treating Auditory Dysfunctions
ES2236551T3 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
EP4395753A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
KR20240057401A (ko) 파라잔틴-기반 카페인 대용 조성물 및 느린 카페인 대사자에서의 이의 사용 방법
ES2385702T3 (es) Antagonistas de A2A para uso en el tratamiento de trastornos de la motricidad
CN106456606A (zh) 吲哚基及吲哚啉基异羟肟酸于治疗神经退化病症或认知缺乏的用途
WO2023101866A1 (en) Fenfluramine for treatment of conditions associated with spreading depolarization
KR101896441B1 (ko) 국소투여형의 연하장애 개선용 의약품
ES2989515T3 (es) Fármaco profiláctico o terapéutico para enfermedades neurodegenerativas
CN104411308B (zh) 通过给予某些合成化合物治疗阿尔茨海默病的方法
HK1222552B (en) Sobetirome in the treatment of myelination diseases
US20210369720A1 (en) Synergistic composition having neuroprotective properties and methods of use thereof
RU2345778C1 (ru) Способ лечения расстройств эрекции у мужчин
GB2547241A (en) Anti-inflammatory formulation
RU2345763C1 (ru) Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин
ES2277567A1 (es) Compuestos con propiedades neuroprotectoras.
ES2575736T3 (es) Composición de extractos ricos en elagitaninos para el bienestar sexual
ES2946699A1 (es) Extracto de cerebro de cerdo y su uso en el tratamiento de enfermedades neurodegenerativas
ITUB20153895A1 (it) Associazione di curcumina, arginina e vitamina d
KR20160018806A (ko) 연하장애 개선용 의약품
Fedorov et al. COMPARATIVE ANALYSIS OF CLINICAL AND IMMUNOLOGICAL INDICATORS OF PHARMACOREISTITENIC PATIENTS WITH SCHIZOPHRENIA COMBODY WITH TUBERCULOSIS OF LUNGS WHEN PURPOSE OF FLUANXOL AND CYCLOPHERON
CA2944750A1 (fr) Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci